Adagene Inc. Stock Price, News & Analysis

Adagene Inc. (Nasdaq: ADAG) announced its participation in several investor and industry conferences throughout November 2021. Key events include one-on-one meetings during the Goldman Sachs Asia Pacific Healthcare Forum from November 15-17, its presentation at the 8th Annual BioCentury-BayHelix China Healthcare Summit from November 16-19, and on-demand viewing of its presentation at the Jefferies London Healthcare Conference starting November 18. Additionally, an on-demand presentation for the Piper Sandler 33rd Annual Virtual Healthcare Conference will be available from November 22.

Adagene Inc. (Nasdaq: ADAG) announced the presentation of promising preclinical data for its antibody candidates ADG153 (anti-CD47 SAFEbody) and ADG152 (CD20xCD3 POWERbody). These candidates aim to tackle development challenges in immuno-oncology. Notable performance includes ADG153's strong anti-tumor activity with minimal liabilities and ADG152 showing an enhanced therapeutic index. The results will be presented at the ASH Annual Meeting in December 2021, with implications for potential Investigational New Drug applications.

Adagene has initiated a phase 1b/2 clinical trial of ADG106, an anti-CD137 agonist antibody, in combination with Nivolumab, targeting advanced non-small cell lung cancer (NSCLC). Conducted at the National University Cancer Institute, Singapore, this trial aims to evaluate safety, tolerability, and anti-tumor efficacy in up to 53 patients who have failed prior treatments. The promising pre-clinical results suggest potential for ADG106 to enhance T-cell activity and address resistance to current therapies.

Adagene Inc. (Nasdaq: ADAG) announced on October 21, 2021, that CEO Peter Luo, Ph.D., will provide a corporate update at the Jefferies Virtual China Biotech Summit on October 26, 2021, at 3:00 p.m. Eastern. The online presentation will offer investors insights into Adagene’s advancements in antibody-based immunotherapies. A live webcast will be available on the company’s website, with a replay accessible for at least 30 days. Adagene leverages AI and computational biology to develop novel immunotherapy solutions using its proprietary Dynamic Precision Library platform.

Adagene Inc. (Nasdaq: ADAG), a clinical-stage biopharmaceutical company, announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 9-15, 2021. Peter Luo, Co-founder and CEO, will present on September 10, 2021, at 2:00 p.m. Eastern. A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days. Adagene focuses on antibody-based cancer immunotherapies, leveraging its proprietary Dynamic Precision Library platform to meet unmet patient needs.

Adagene reported significant advancements in its oncology pipeline, establishing three collaborations with Merck for global combination trials involving pembrolizumab. Their lead candidate, ADG106, displayed a 56% disease control rate in monotherapy trials. Additionally, ADG116 and ADG126 are progressing through phase 1 trials, showcasing promising safety profiles. Financially, cash reserves increased to $208.3 million, attributed to a successful IPO. However, the company faced a net loss of $37.2 million for the first half of 2021, up from $18.2 million the previous year.

Adagene Inc. announces a collaboration with Merck to evaluate its product candidate ADG106 in combination with KEYTRUDA for patients with advanced or metastatic malignancies. This third clinical trial, designated ADG106-P2001/KEYNOTE-D12, follows promising Phase I trial data. ADG106, developed using the NEObody platform, targets CD137 to activate the immune response against cancer cells. The study aims to address significant unmet medical needs for patients unresponsive to existing treatments.

Adagene Inc. (Nasdaq: ADAG) announced key appointments to its leadership team, including Steven Fischkoff as interim Chief Medical Officer and new members of its Scientific and Strategic Advisory Board. This team comprises experts with extensive backgrounds in immuno-oncology, aimed at revolutionizing cancer therapeutics. Their experience includes pivotal roles in developing major immunotherapy products. CEO Peter Luo expressed confidence that these appointments will enhance Adagene's capabilities in global clinical development and the advancement of its innovative antibody-based pipeline.

Adagene Inc. (Nasdaq: ADAG) announced a collaboration with Merck to conduct two clinical studies assessing the NEObody™ candidate, ADG116, and the SAFEbody™ candidate, ADG126, combined with KEYTRUDA® for patients with advanced solid tumors. Both studies aim to evaluate the safety and efficacy of these candidates in enhancing therapeutic outcomes while addressing historical safety concerns with CTLA-4 therapies. Preliminary data suggests favorable tolerability and promising early outcomes, marking essential progress in Adagene's clinical development program.